News not to be missed

Global growth is exciting — but are you fully prepared for the complexities of managing international teams? Join us as we demystify Deel, Remote and other Employer of Record (EOR) solutions, exploring how startups can leverage them for rapid expansion..

SEB invested €1.5 million in the Estonian technology company, CybExer Technologies, through its new Baltic Venture Debt investment programme. Founded in 2016, CybExer Technologies is a NATO award-winning cybersecurity testing and training solutions company that enables organisations around the world..

This Frequently Asked Questions (FAQ) document provides a concise overview of the Latvian public procurement rules. It is designed to assist foreign candidates and bidders in navigating the complexities of the public procurement process in Latvia. By addressing common queries..

COBALT’s pro bono work in Latvia has been recognized in the newly published Chambers DEI Global Report 2024. This comprehensive report examines key themes, case studies, and emerging trends in diversity, equity, and inclusion (DEI) and pro bono initiatives globally...

Mehiläinen, Finland’s largest provider of social and healthcare services, has acquired the Lithuanian private medical services network, InMedica Group. The sale was agreed upon by the private equity fund INVL Baltic Sea Growth Fund, the healthcare services and pharmaceutical manufacturing..

COBALT is delighted to announce that Maija Tipaine, Senior Associate and Certified Mediator, has been appointed as a member to the Patent Mediation and Arbitration Centre (PMAC) Expert Committee. This appointment recognizes Maija’s exceptional qualifications and expertise in both patent..

As of 2 January 2025, Dace Silava-Tomsone, Managing Partner of COBALT Latvia, has been appointed Chairwoman of the COBALT Baltic Board. She succeeds Irmantas Norkus, Managing Partner of COBALT Lithuania, who will continue to serve as a member of the..

The article was published in CEE Legal Matters magazine October 2024. It is not new that originator pharmaceutical companies try to block generic competitors from entering the market. Considering the recent developments in the Court of Justice of the European..